Ferrari R, Ford I, Fox K, et al. - Researchers undertook this randomised, double-blind, placebo-controlled, event-driven trial to determine the long-term potential advantages as well as safety of trimetazidine added to standard evidence-based medical treatment among patients who had a recent successful percutaneous coronary intervention (PCI). Participants were recruited from 365 centres in 27 countries across Europe, South America, Asia, and north Africa. Eligible patients were randomized to oral trimetazidine 35 mg modified-release twice daily or matching placebo. As per findings, recurrence of angina or the outcome, following successful PCI, remained unaffected by routine use of oral trimetazidine 35 mg twice daily over several years in patients receiving optimal medical therapy; these observations are suggested to be kept in mind when considering the place of trimetazidine in clinical practice. However, the long-term implementation of this treatment did not seem to be related to any statistically significant safety concerns in the population examined.